Press release
Focal Segmental Glomerulosclerosis Market to Witness Promising Upswing by 2034, DelveInsight Forecasts
To Know in detail about the Focal Segmental Glomerulosclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Focal Segmental Glomerulosclerosis Market Forecast
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Focal Segmental Glomerulosclerosis Market Report:
• The Focal Segmental Glomerulosclerosis market size was valued approximately USD 734 Million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, Travere Therapeutics, Inc. announced that it will present three abstracts, including a late-breaking oral presentation, at the 2025 National Kidney Foundation (NKF) Spring Clinical Meetings, scheduled for April 10-13 in Boston, MA. The late-breaking session will showcase new analyses from the Phase III DUPLEX Study of FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), highlighting that partial and complete proteinuria remission occurred earlier and more frequently with FILSPARI compared to irbesartan. The data also indicated that patients achieving proteinuria remission experienced low rates of kidney failure.
• In December 2024, Dimerix Limited announced that the first 144 patients have been randomized in the DMX-200 ACTION3 Phase III clinical trial for FSGS kidney disease. After enrollment, patients complete a background medication stabilization phase before being assigned to receive either DMX-200 or a placebo.
• In March 2024, ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or u201CZyVersau201D) has reached a significant milestone with the initiation of its first-in-human clinical trial for VAR 200. This trial aims to validate the promising preclinical outcomes observed across three distinct animal models of kidney diseaseu2014diabetic kidney disease, focal segmental glomerulosclerosis, and Alport syndromeu2014and determine their applicability to patients with kidney disease.
• In 2022, the US accounted for approximately 34% of the total FSGS market, with projections indicating a significant compound annual growth rate (CAGR) during the study period.
• In 2022, the EU4 countries and the UK generated an estimated USD 147 million, with this figure expected to grow at a significant CAGR. Among the European nations, France held the largest market share in 2022, followed by Germany.
• According to DelveInsight's assessments, there were roughly 55 million diagnosed prevalent cases of FSGS in the 7MM in 2022, with expectations of a rise during the forecast period.
• In 2022, around 26 million individuals in the United States were diagnosed with FSGS, and this number is projected to rise at an estimated CAGR throughout the study period from 2020 to 2034.
• In EU4 and the UK, Germany had the largest diagnosed prevalent population of FSGS in 2022, with approximately 5 million cases, followed by France and Italy. Conversely, Spain had the lowest diagnosed prevalent population in EU4 and the UK in 2022.
• Key Focal Segmental Glomerulosclerosis Companies: Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others
• Key Focal Segmental Glomerulosclerosis Therapies: EG-102, OCX-063, R3R 01, BI764198, DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others
• The Focal Segmental Glomerulosclerosis epidemiology based on gender analyzed that Focal Segmental Glomerulosclerosis is more prevalent in males than females in the United States
• The Focal Segmental Glomerulosclerosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Focal Segmental Glomerulosclerosis pipeline products will significantly revolutionize the Focal Segmental Glomerulosclerosis market dynamics.
Focal Segmental Glomerulosclerosis Overview
Focal Segmental Glomerulosclerosis (FSGS) is a rare kidney disorder characterized by scarring (sclerosis) of some of the kidney's glomeruli, which are the small filtering units. This scarring can lead to protein leakage into the urine, kidney dysfunction, and eventually kidney failure if untreated. FSGS can be primary (idiopathic) or secondary, caused by other conditions like infections, obesity, or genetic factors. Symptoms may include swelling, high blood pressure, and foamy urine. Treatment typically involves managing symptoms and preventing further kidney damage.
Get a Free sample for the Focal Segmental Glomerulosclerosis Market Report:
https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Focal Segmental Glomerulosclerosis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Focal Segmental Glomerulosclerosis Epidemiology Segmentation:
The Focal Segmental Glomerulosclerosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Focal Segmental Glomerulosclerosis
• Prevalent Cases of Focal Segmental Glomerulosclerosis by severity
• Gender-specific Prevalence of Focal Segmental Glomerulosclerosis
• Diagnosed Cases of Episodic and Chronic Focal Segmental Glomerulosclerosis
Download the report to understand which factors are driving Focal Segmental Glomerulosclerosis epidemiology trends @ Focal Segmental Glomerulosclerosis Epidemiology Forecast
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Focal Segmental Glomerulosclerosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Focal Segmental Glomerulosclerosis market or expected to get launched during the study period. The analysis covers Focal Segmental Glomerulosclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Focal Segmental Glomerulosclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Focal Segmental Glomerulosclerosis Therapies and Key Companies
• EG-102: Evergreen Therapeutics
• OCX-063: Certa Therapeutics
• R3R 01: River 3 Renal Corp
• BI764198: Boehringer Ingelheim
• DMX200: Dimerix Bioscience
• Sparsentan: Travere Therapeutics
• DMX-200: Dimerix
• GFB-887: Goldfinch Bio
• VX-147: Vertex Pharmaceuticals
• Losmapimod: GlaxoSmithKline
• Propagermanium: Dimerix Bioscience Pty Ltd
• RE-021 (Sparsentan): Travere Therapeutics, Inc.
• CCX140-B: ChemoCentryx
• Dapagliflozin: AstraZeneca
• rituximab: Genentech, Inc.
• fresolimumab: Sanofi
• Acthar Gel: Mallinckrodt ARD LLC
• VB119: ACELYRIN Inc.
• Bleselumab: Kyowa Kirin Co., Ltd.
• Abatacept: Bristol-Myers Squibb
Discover more about therapies set to grab major Focal Segmental Glomerulosclerosis market share @ Focal Segmental Glomerulosclerosis Treatment Market
https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Focal Segmental Glomerulosclerosis Market Strengths
• The frequency of Focal Segmental Glomerulosclerosis appears to be increasing worldwide, which presents a promising opportunity for various companies to develop novel therapies
• The advent of next-generation sequencing promises to provide nephrologists with rapid and novel approaches for diagnosing and treating Focal Segmental Glomerulosclerosis
• A stratified and targeted approach is being evolved based on the underlying molecular defects
Focal Segmental Glomerulosclerosis Market Unmet Needs
• Heterogeneity in the disease presentation
• The requirement for cutting-edge diagnosis
• Restricted specific epidemiological studies
• Inadequate therapeutic options
Scope of the Focal Segmental Glomerulosclerosis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Focal Segmental Glomerulosclerosis Companies: Evergreen Therapeutics, Certa Therapeutics, River 3 Renal Corp, Boehringer Ingelheim, Dimerix Bioscience, Travere Therapeutics, Dimerix, Goldfinch Bio, Vertex Pharmaceuticals, GlaxoSmithKline, Dimerix Bioscience Pty Ltd, ChemoCentryx, AstraZeneca, Genentech, Inc., Sanofi, Mallinckrodt ARD LLC, ACELYRIN Inc., Kyowa Kirin Co., Ltd., Bristol-Myers Squibb, and others
• Key Focal Segmental Glomerulosclerosis Therapies: EG-102, OCX-063, R3R 01, BI764198, DMX-200, GFB-887, VX-147, Losmapimod, Propagermanium, RE-021 (Sparsentan), CCX140-B, Dapagliflozin, rituximab, fresolimumab, Acthar Gel, VB119, Bleselumab, Abatacept, and others
• Focal Segmental Glomerulosclerosis Therapeutic Assessment: Focal Segmental Glomerulosclerosis current marketed and Focal Segmental Glomerulosclerosis emerging therapies
• Focal Segmental Glomerulosclerosis Market Dynamics: Focal Segmental Glomerulosclerosis market drivers and Focal Segmental Glomerulosclerosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Focal Segmental Glomerulosclerosis Unmet Needs, KOL's views, Analyst's views, Focal Segmental Glomerulosclerosis Market Access and Reimbursement
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Focal Segmental Glomerulosclerosis Market to Witness Promising Upswing by 2034, DelveInsight Forecasts here
News-ID: 4148581 • Views: …
More Releases from DelveInsight Business Research
Global Injectable Drug Delivery Devices Market to grow at a CAGR of 11.26% by 20 …
According to DelveInsight's analysis, The growth in demand for injectable drug delivery devices is largely driven by the rising prevalence of chronic diseases like cancer, diabetes, and cardiovascular disorders, the increasing adoption of self-injectors, expansion of the biologics and biosimilars market, the growing emphasis on patient compliance with treatments, and continuous innovations and technological advancements in the field.
DelveInsight's "Injectable Drug Delivery Devices Market Insights, Competitive Landscape and Market Forecast-2030" report…
Abdominal Aortic Aneurysm Market Expected to Gain Momentum Through 2034, Accordi …
DelveInsight's "Abdominal Aortic Aneurysm Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Abdominal Aortic Aneurysm, historical and forecasted epidemiology as well as the Abdominal Aortic Aneurysm market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Abdominal Aortic Aneurysm market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Abdominal Aortic Aneurysm…
Frontotemporal Dementia Pipeline 2025: Therapies Under Investigation, Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Frontotemporal Dementia pipeline constitutes 15+ key companies continuously working towards developing 20+ Frontotemporal Dementia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Frontotemporal Dementia Pipeline Insight, 2025 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Frontotemporal Dementia Market.
The Frontotemporal…
Heart Failure Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and K …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Heart Failure pipeline constitutes 70+ key companies continuously working towards developing 75+ Heart Failure treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Heart Failure Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Heart Failure Market.
The Heart…
More Releases for Focal
Focal Segmental Glomerulosclerosis Market Size Report 2024
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Focal Segmental Glomerulosclerosis Drugs Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $22.41 billion In…
Subwoofers Market Disclosing Latest Advancement 2021 to 2027 | Dual, Focal
This Subwoofers market report breaks down the market into segments and sub-segments. With this market analysis, managing the outline of the industries gets simple. This Subwoofers market report also assists in making informed decisions by giving unique industry insights as well as historical and projected industry data. It presents a worldwide market scenario to assist important companies in establishing themselves and surviving in the market. This Subwoofers market report analysis…
3D FOCAL LINES SPATULA TECHNOLOGY for SYGMALIFT
Focal Ultrasounds in three-dimensional (3D) technology expand to the Face Lifting and V Facing. This innovation is able to treat volume that contains every conceivable plane (X, Y, Z angles) within the region of interest such as Double Chin or Cheeks.
While there is no doubt that there are advantages to volume treatment in 2.5 Seconds only, it delivers more power and add clinical benefit to target submental and jawlines…
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2018
Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, anad is very common in African American population.
Download the sample report @ https://www.pharmaproff.com/request-sample/1090
FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two…
Focal Segmental Glomerulosclerosis (FSGS) Market Report 2018: Segmentation by Di …
Global Focal Segmental Glomerulosclerosis (FSGS) market research report provides company profile for Variant Pharmaceuticals, Inc., GlaxoSmithKline plc., Novartis AG, ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., AstraZeneca plc., Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth…
Africa Energy Week – Three Different Focal Points, One Conference
Africa’s development in oil and gas has significantly increased over the last few years; Ghana’s Jubilee field, first discovered in 2007, is now producing 70,000 barrels a day and may climb to 120,000 by the end of the year. With much of its oil for export, the country’s economic growth is climbing at a rapid rate, and many are looking to follow suit. Local content has since been a hot…
